DOI: https://doi.org/10.22141/2224-1507.8.2.2018.137192

Osteoporosis in oncology

V.V. Povoroznyuk, M.A. Bystrytska, A.S. Musiienko

Abstract


Osteoporosis often develops in patients with oncology as a result of direct impact on the bone of tumor process and antitumor treatment (chemotherapy, radiation therapy, androgenic or estrogen deprivation). The article reviews the literature on osteoporosis in oncology and outlines several ge­neral recommendations for managing this category of patients. A clinical case of metastatic spine injury in a patient with osteoporosis is presented.

Keywords


oncologic pathology; neoplasm; osteoporosis; review

References


Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R. Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv. 2009 Jun;3(2):75-88. doi: 10.1007/s11764-009-0083-4.

Shahinian V, Kuo Y, Freeman J, Goodwin JS. Risk of fracture after androgendeprivation for prostate cancer. N Engl J Med. 2005 Jan 13;352(2):154-64. doi: 10.1056/NEJMoa041943.

Smith M, Lee W, Brandman J, Wang Q, Wang Q, Botteman M, Pashos CL. Gonadotropin‑releasing hormone agonists and fracture risk: a claims‑basedcohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005 Nov 1;23(31):7897-903. doi: 10.1200/JCO.2004.00.6908.

Smith M, Malkowicz S, Chu F, et al. Toremifene increases bonemineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study. J Urol. 2008 Jan;179(1):152-5. doi: 10.1016/j.juro.2007.08.137.

Handforth C, D'Oronzo S, Coleman R, Brown J. Cancer Treatment and Bone Health. Calcif Tissue Int. 2018 Feb;102(2):251-264. doi: 10.1007/s00223-017-0369-x.

Watts N, Adler R, Bilezikian J, et al. Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012 Jun;97(6):1802-22. doi: 10.1210/jc.2011-3045.

de Bono JS, Logothetis C, Molina A, et al; COU‑AA‑301 Investigators. Abiraterone and increased survival in metastatic prostate. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.

de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration‑resistant prostate cancer progressing after docetaxel treatment: a randomised open‑label trial. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.

Kanis J, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001 Dec;12(12):989-95. DOI: 10.1007/s001980170006.

Diamond T, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo‑controlled crossover study. Cancer. 2001 Sep 15;92(6):1444-50.

Michaelson M, Kaufman D, Lee H, et al. Randomizedcontrolled trial of annual zoledronic acid to prevent gonadotropin‑releasing hormoneagonist‑induced bone loss in men with prostate cancer. J Clin Oncol. 2007 Mar 20;25(9):1038-42. doi: 10.1200/JCO.2006.07.3361.

Smith M, Egerdie B, Hernandez Toriz N, et al; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen‑deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003.

Smith M, Morton R, Barnette K, et al. Toremifene to reduce fracture risk in menreceiving androgen deprivation therapy for prostate cancer. J Urol. 2010 Oct;184(4):1316-21. doi: 10.1016/j.juro.2010.06.022.

Lønning E, Eikesdal H. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer. 2013 Jun 24;20(4):R183-201. doi: 10.1530/ERC-13-0099.

Saarto T, Blomqvist C, Valimaki M, Mäkelä P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluoracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997 Apr;15(4):1341-7. doi: 10.1200/JCO.1997.15.4.1341.

Delmas P, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo controlled study. J Clin Oncol. 1997 Mar;15(3):955-62. doi: 10.1200/JCO.1997.15.3.955.

Shapiro C, Manola J, LeBoff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with premenopausal early-stage breast cancer. J Clin Oncol. 2001 Jul 15;19(14):3306-11. doi: 10.1200/JCO.2001.19.14.3306.

Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node positive breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). Osteoporos Int. 2003 Dec;14(12):1001-6. doi: 10.1007/s00198-003-1508-y.

Eastell R, AdamsJ, Coleman R, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008 Mar 1;26(7):1051-7. doi: 10.1200/JCO.2007.11.0726.

Perez E, Josse R, Pritchard K, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCICCTG MA.17. J Clin Oncol. 2006 Aug 1;24(22):3629-35. doi: 10.1200/JCO.2005.05.4882.

Love R, Mazess R, Barden H, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992 Mar 26;326(13):852-6. doi: 10.1056/NEJM199203263261302.

Powles T, Hickish T, Kanis J, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996 Jan;14(1):78-84. doi: 10.1200/JCO.1996.14.1.78.

Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747-57. doi: 10.1056/NEJMoa052258.

Younis H, Farhat G, El-Hajj Fuleihan G. Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass. J Clin Densitom. 2002 Summer;5(2):143-9.

Brufsky A, Harker W, Beck J, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast Cancer patients receiving letrozole. Cancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313.

Llombart A, Frassoldati A, Paija O, et al. Immediate administration of zoledronic acid reduces aromatase Inhibitor-Associated bone loss in postmenopausal women with early breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012 Feb;12(1):40-8. doi: 10.1016/j.clbc.2011.08.002.

He M, Fan W, Zhang X. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis. J Hematol Oncol. 2013 Oct 23;6(1):80. doi: 10.1186/1756-8722-6-80.

Hadji P, Aapro M, Body J, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol. 2017 Mar 23;7:1-12. doi: 10.1016/j.jbo.2017.03.001.

Lim JS, Lee JI. Prevalence, pathophysiology, screening and management of osteoporosis in gastric cancer patients. J Gastric Cancer. 2011 Mar;11(1):7-15. doi: 10.5230/jgc.2011.11.1.7.

Lim JS, Kim SB, Bang HY, Cheon GJ, Lee JI. High prevalence of osteoporosis in patients with gastric adenocarcinoma following gastrectomy. World J Gastroenterol. 2007 Dec 28;13(48):6492-7.

Yoo SH, Lee JA, Kang SY, et al. Risk of osteoporosis after gastrectomy in long-term gastric cancer survivors. Gastric Cancer. 2017 Nov 21. doi: 10.1007/s10120-017-0777-7. [Epub ahead of print].

Bisballe S, Eriksen EF, Melsen F, Mosekilde L, Sørensen OH, Hessov I. Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodelling, vitamin D metabolites, and bone histomorphometry. Gut. 1991 Nov;32(11):1303-7.

Lee MY, Park JH, Bae KS, et al. Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer. Ann Surg Treat Res. 2014 Feb;86(2):55-60. doi: 10.4174/astr.2014.86.2.55.

Lin SY, Lin CL, Chen HT, Kao CH. Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study. Curr Med Res Opin. 2018 May;34(5):805-812. doi: 10.1080/03007995.2017.1378174.

de Melo TG, da Assumpção LV, Santos Ade O, Zantut-Wittmann DE. Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma. Thyroid Res. 2015 Jun 2;8:7. doi: 10.1186/s13044-015-0019-1.

Rachner TD, Coleman R, Hadji P, Hofbauer LC. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018 Mar 20. pii: S2213-8587(18)30047-0. doi: 10.1016/S2213-8587(18)30047-0. [Epub ahead of print].

Povoroznyuk VV, Grygorieva NV, Dzerovych NI, et al. Information letter. On innovations in the health care system. Method for assessing the risk of osteoporosis and its complications at the primary level of medical care. Bolʹ, sustavy, pozvonočnik. 2018:8(1):52-53. doi: 10.22141/2224-1507.8.1.2018.130701.

Coleman R, Body JJ, Aapro M, Hadji P4, Herrstedt J5; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014 Sep;25 Suppl 3:iii124-37. doi: 10.1093/annonc/mdu103.




Copyright (c) 2018 PAIN. JOINTS. SPINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта